Epac is identified as a novel positive regulator of cardiac growth, mediating cAMP-induced cardiomyocyte hypertrophy via Rac and calcineurin/NFAT signaling.
Answers are grounded in this paper and cite their sources.
Epac pathway merits testing in hypertrophy models; leaves open any role in human cardiac remodeling or therapy.
cAMP is one of the most important second messenger in the heart. The discovery of Epac as a guanine exchange factor (GEF), which is directly activated by cAMP, raises the question of the role of this protein in cardiac cells. Here we show that Epac activation leads to morphological changes and induces expression of cardiac hypertrophic markers. This process is associated with a Ca2+-dependent activation of the small GTPase, Rac. In addition, we found that Epac activates a prohypertrophic signaling pathway, which involves the Ca2+ sensitive phosphatase, calcineurin, and its primary downstream effector, NFAT. Rac is involved in Epac-induced NFAT dependent cardiomyocyte hypertrophy. Blockade of either calcineurin or Rac activity blunts the hypertrophic response elicited by Epac indicating these signaling molecules coordinately regulate cardiac gene expression and cellular growth. Our results thus open new insights into the signaling pathways by which cAMP may mediate its biological effects and identify Epac as a new positive regulator of cardiac growth.
No takes yet. Share an insight, caveat, or question.
Morel et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: